NCT05312021View on ClinicalTrials.gov

Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2022

Primary Completion Date

September 30, 2023

Study Completion Date

November 30, 2023

Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
DRUG

IMR-687

150 mg and 200 mg tablets

OTHER

IMR-687 Placebo

Matching placebo to IMR-687

Sponsors
All Listed Sponsors
collaborator

Imara, Inc.

INDUSTRY

lead

Cardurion Pharmaceuticals, Inc.

INDUSTRY